Article

Molecular Neurobiology

, Volume 36, Issue 1, pp 60-67

Cannabinoids and Gliomas

  • Guillermo VelascoAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Arkaitz CarracedoAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Cristina BlázquezAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Mar LorenteAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Tania AguadoAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Amador HaroAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Cristina SánchezAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Ismael Galve-RoperhAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University
  • , Manuel GuzmánAffiliated withDepartment of Biochemistry and Molecular Biology I, School of Biology, Complutense University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Cannabinoids, the active components of Cannabis sativa L., act in the body by mimicking endogenous substances—the endocannabinoids—that activate specific cell surface receptors. Cannabinoids exert various palliative effects in cancer patients. In addition, cannabinoids inhibit the growth of different types of tumor cells, including glioma cells, in laboratory animals. They do so by modulating key cell signaling pathways, mostly the endoplasmic reticulum stress response, thereby inducing antitumoral actions such as the apoptotic death of tumor cells and the inhibition of tumor angiogenesis. Of interest, cannabinoids seem to be selective antitumoral compounds, as they kill glioma cells, but not their non-transformed astroglial counterparts. On the basis of these preclinical findings, a pilot clinical study of Δ9-tetrahydrocannabinol (THC) in patients with recurrent glioblastoma multiforme has been recently run. The good safety profile of THC, together with its possible growth-inhibiting action on tumor cells, justifies the setting up of future trials aimed at evaluating the potential antitumoral activity of cannabinoids.

Keywords

Cannabinoid Receptor Glioma Cancer Apoptosis Angiogenesis Experimental therapeutics Clinical trial